All Updates

All Updates

icon
Filter
Funding
Athos Therapeutics raises USD 35 million Series B to develop treatments for autoimmune diseases
AI Drug Discovery
Feb 16, 2024
This week:
Funding
EKORE raises EUR 1.3 million (~ USD 1 million) in seed funding to strengthen platform
Digital Twin
Dec 20, 2024
Funding
Culina Health raises USD 7.9 million in Series A funding to expand offerings and expand team
Functional Nutrition
Dec 19, 2024
FDA approval
ViGeneron receives IND clearance for VG801 gene therapy
Cell & Gene Therapy
Dec 19, 2024
Product updates
Reflex Aerospace ships first commercial satellite SIGI
Next-gen Satellites
Dec 19, 2024
Partnerships
Vast partners with SpaceX for two private astronaut missions to ISS
Space Travel and Exploration Tech
Dec 19, 2024
Management news
Carbios appoints Philippe Pouletty as interim CEO amid plant delay
Waste Recovery & Management Tech
Dec 19, 2024
Funding
BlueQubit raises USD 10 million in seed funding to develop quantum platform
Quantum Computing
Dec 19, 2024
FDA approval
Arbor Biotechnologies receives FDA clearance for ABO-101 IND application
Human Gene Editing
Dec 19, 2024
Funding
Partnerships
Personalis partners with Merck and Moderna for cancer therapy development and investment
Precision Medicine
Dec 19, 2024
Partnerships
COTA partners with Guardant Health to develop clinicogenomic data solutions for cancer research
Precision Medicine
Dec 19, 2024
AI Drug Discovery

AI Drug Discovery

Feb 16, 2024

Athos Therapeutics raises USD 35 million Series B to develop treatments for autoimmune diseases

Funding

  • California-based AI drug discovery company Athos Therapeutics has secured USD 35 million in a Series B funding round. The investors were not disclosed.

  • The proceeds will support the development of treatments for autoimmune diseases and cancer, with USD 10 million specifically allocated to develop treatments for inflammatory bowel disease (IBD).

  • Founded in 2019, Athos Therapeutics develops novel small-molecule precision therapeutics targeting autoimmune diseases and cancers using AI-based medicinal chemistry and computational platforms. It also maintains a database of clinical and molecular datasets to identify novel drug targets. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.